why choose us

First received: September 08, 2023

Clinical Trial: Medicare Anti-A? mAb Coverage With Evidence Development (CED) Study

Study Status: Completed

Recruit Status: RECRUITING

Condition: Mild Alzheimer's Disease

Study Type: OBSERVATIONAL


Official Title: Prospective Study on Anti-Amyloid-? Monoclonal Antibodies Directed Against Amyloid for the Treatment of Alzheimer's Disease Coverage of Evidence Development (The Anti-A? mAb CED Study)

Brief Summary: The Anti-A? mAb CED Study is a prospective, longitudinal coverage with evidence development (CED) study using clinical data, patient assessments, and administrative claims data of the Medicare population, conducted in accordance to the National Coverage Determination (NCD) on Monoclonal Antibodies Directed Against Amyloid for the Treatment of Alzheimer's Disease (AD).

Read more